Cost-Effectiveness of Primary versus Secondary Prophylaxis with Pegfilgrastim in Women with Early-Stage Breast Cancer Receiving Chemotherapy  by Ramsey, Scott D. et al.
Cost-Effectiveness of Primary versus Secondary Prophylaxis
with Pegﬁlgrastim inWomen with Early-Stage Breast Cancer
Receiving Chemotherapy
Scott D. Ramsey, MD, PhD,1 Zhimei Liu, PhD,2 Rob Boer, PhD,3 Sean D. Sullivan, PhD,4 Jennifer Malin, MD, PhD,5
Quan V. Doan, PharmD,2 RobertW. Dubois, MD, PhD,2 Gary H. Lyman, MD, MPH, FRCP (Edin)6
1Fred Hutchinson Cancer Research Center and University ofWashington Department of Medicine, Seattle,WA, USA; 2Cerner LifeSciences,
Beverly Hills, CA, USA; 3Consultant to Amgen, Santa Monica, CA, USA; 4University ofWashington School of Pharmacy, Seattle,WA, USA;
5JAmgen Inc.,Thousand Oaks, CA, USA; 6Duke University and the Duke Comprehensive Cancer Center, Durham, NC, USA
ABSTRACT
Objective: Prophylaxis with granulocyte colony-stimulating factor
(G-CSF) reduces the risk of febrile neutropenia (FN) in patients receiving
myelosuppressive chemotherapy. We estimated the incremental cost-
effectiveness of G-CSF pegﬁlgrastim primary (starting in cycle 1 and
continuing in subsequent cycles of chemotherapy) versus secondary (only
after an FN event) prophylaxis in women with early-stage breast cancer
receiving myelosuppressive chemotherapy with a 20% FN risk.
Methods: A decision-analytic model was constructed from a health insur-
er’s perspective with a lifetime study horizon. The model considers direct
medical costs and outcomes related to reduced FN and potential survival
beneﬁts because of reduced FN-related mortality. Inputs for the model
were obtained from the medical literature. Sensitivity analyses were
conducted across plausible ranges in parameter values.
Results: The incremental cost-effectiveness ratio (ICER) of pegﬁlgrastim as
primary versus secondary prophylaxis was $48,000/FN episode avoided.
Adding survival beneﬁt from avoiding FN mortality yielded an ICER of
$110,000/life-year gained (LYG) or $116,000/quality-adjusted life-year
(QALY) gained. The most inﬂuential factors included FN case-fatality, FN
relative risk reduction from primary prophylaxis, and age at diagnosis.
Conclusions: Compared with secondary prophylaxis, the cost-
effectiveness of pegﬁlgrastim as primary prophylaxis may be equivalent or
superior to other commonly used supportive care interventions for women
with breast cancer. Further assessment of the direct impact of G-CSF on
short- and long-term survival is needed to substantiate these ﬁndings.
Keywords: breast cancer, cost-effectiveness, pegﬁlgrastim, primary
prophylaxis.
Introduction
Severe neutropenia (low white blood cell count) is a major unto-
ward effect of chemotherapy, predisposing patients to bacterial
infections that can be life threatening. Severe neutropenia and
febrile neutropenia (FN) (low white blood cell count and fever,
indicators of potential infection) in particular often prompt phy-
sicians to reduce chemotherapy doses, which may lower tumor
response rates in the metastatic setting and increase the risk of
cancer relapse in the adjuvant setting. The granulocyte-colony
stimulating factors (G-CSFs) can reduce the incidence, duration,
and severity of chemotherapy-induced neutropenia and related
complications [1–6].
In the recent American Society of Clinical Oncology (ASCO),
National Comprehensive Cancer Network (NCCN), and Euro-
pean Organization for Research and Treatment of Cancer
(EORTC) guidelines, primary prophylaxis with G-CSF is recom-
mended from the ﬁrst cycle of chemotherapy when the overall risk
of FN is at least 20% [1,7,8]. Although most clinical trials have
evaluated G-CSF at the onset of chemotherapy (primary prophy-
laxis) compared with either no G-CSF or after an FN event, herein
referred to as secondary prophylaxis, retrospective studies suggest
that clinicians often useG-CSF later in the course of chemotherapy
in response to severe neutropenia or after patients develop FN
[1,7–10]. Using G-CSF as secondary prophylaxis will decrease
G-CSF expenditures, but may also expose patients to more FN
events, with associated morbidity and mortality risks and costs,
and may also result in chemotherapy dose reductions or delays.
Given these tradeoffs, the purpose of this studywas to estimate the
cost-effectiveness of pegﬁlgrastim (Neulasta, Amgen Inc., Thou-
sand Oaks, CA) when used as primary versus secondary prophy-
laxis in women with early-stage breast cancer receiving
myelosuppressive chemotherapy with a risk of FN of approxi-
mately 20% or higher.
Several studies have evaluated the economic impact of pro-
phylactic G-CSF in the setting of myelosuppressive chemo-
therapy [11–23]. Nevertheless, these studies primarily compare
the short-term costs of G-CSF versus potential near-term cost
offsets associated with avoiding FN-related medical care. Other
potential short- and long-term health effects associated with
G-CSF include avoiding FN-related mortality and improving sur-
vival from delivering chemotherapy at the planned dose and
schedule. We consider the cost-effectiveness of pegﬁlgrastim in
the setting of primary prophylaxis for breast cancer patients
receiving myelosuppressive chemotherapy.
Methods
Study Population
The study population included women aged 30 to 80 years with
stage I to III breast cancer receiving myelosuppressive chemo-
therapy (e.g., docetaxel, doxorubicin/docetaxel, or docetaxel/
doxorubicin/cyclophosphamide [TAC]) with an FN risk of
approximately 20%. The reference patient was 49 years old with
stage II breast cancer receiving six cycles of chemotherapy.
Design of the Decision Analysis Model
A decision analytic model was constructed from a health payer’s
perspective (Fig. 1). The model considered a woman with breast
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Figure 1 Model structure. FN, febrile neutropenia; RDI, relative dose intensity.
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cancer receiving myelosuppressive chemotherapy and considered
two treatment strategies: pegﬁlgrastim primary prophylaxis
and pegﬁlgrastim secondary prophylaxis. The model followed
the patient until death from cancer or other causes. During the
course of chemotherapy, the patient may experience an FN event,
and as a result is at risk of dying from that event. As an extension
to the model (used only in the sensitivity analysis), we also
included the probability nodes for a patient to receive chemo-
therapy at a cumulative relative dose intensity (RDI) of <85%,
which is deﬁned as the amount (<85%) of chemotherapy
delivered relative to the standard amount of chemotherapy over
the course of chemotherapy.
The model was based on the FN incidence for a chemo-
therapy course (i.e., across all chemotherapy cycles). Patients
who have one episode of FN are at risk for developing FN in
subsequent cycles [24]. We indirectly modeled these recurring
events by taking into account the cost associated with repeated
hospitalizations. Nevertheless, the risk of mortality and chemo-
therapy dose reductions or dose delays associated with subse-
quent FN events was not captured by the model. Although most
patients who develop FN are hospitalized, selected patients at
lower risk of complications may be managed as outpatients
[25,26]. We assumed that 80% of FN patients were hospitalized
and 20% had outpatient management [15].
Health Care Costs
Costs included pegﬁlgrastim, drug administration, initial FN
hospitalization, repeated FN hospitalizations, and subsequent
FN-related medical costs, such as those at outpatient settings
(Table 1). Direct nonmedical costs (e.g., cost of transportation)
and indirect costs (e.g., lost productivity) were not considered.
Although differences in chemotherapy doses would nominally
affect the cost of chemotherapy, the need to waste whatever
chemotherapy remained would likely limit this difference. In
addition, the cost of adjunctive therapy and staff time would not
be appreciably different even with the difference in chemotherapy
dose. We therefore assumed that both arms of the model would
have essentially the same chemotherapy costs, and accordingly
did not include the cost of chemotherapy delivery in our model.
All costs were adjusted to 2006 US dollars using the Medical
Care Services component of the Consumer Price Index [27].
Pegﬁlgrastim cost was estimated at $2142 per injection per
chemotherapy cycle (average of the 2006 average sales prices for
quarters 1 to 4 [28]). The cost of administering pegﬁlgrastim was
estimated to be $20/injection, obtained by averaging the fees
associated with the Current Procedure Terminology (CPT) codes
99211 (Level One visit) and 90772 (Drug Administration)
[29,30]. Patients receiving primary prophylaxis were assumed to
be receiving one injection of pegﬁlgrastim in each cycle of che-
motherapy. To estimate the cost of pegﬁlgrastim in patients
receiving it for secondary prophylaxis after an FN event, we
assumed that half of the patients who developed FN incurred it
in the ﬁrst cycle [6,31]. For FN events occurring after the ﬁrst
cycle, we assumed that the FN events were uniformly distributed
across the remaining cycles.
Reported costs of FN hospitalization for breast cancer
patients have ranged from $7100 to $12,372 [32–34]. We used
the lower estimate, which was inﬂated to 2006 dollars using the
medical care services component of the Consumer Price Index
[27]. Because inpatient physician fees were not included in this
estimate, we added 10% of the facility cost of FN hospitalization
to account for physician services. The 10% physician fee was a
conservative estimate based on a study on cardiovascular events
and fractures among patients with end-stage renal disease, in
which the authors reported that costs for physician services
during the course of an inpatient stay were approximately 11%
to 17% of the total cost [35]. Although the disease of interest is
different between this study and ours, 10% for physician services
in the United States may be a reasonable assumption. The cost of
related health care after FN hospitalization was estimated to be
40% of the cost for initial FN hospitalization [20% because of
rehospitalization(s) for FN, 20% because of ambulatory services]
based on a study on lung cancer [11] and another that included
52% breast cancer patients [36]. The cost of outpatient FN
management was assumed to be 50% of inpatient management.
A recent study by Bennett et al. [37] reported that the mean
direct cost was 3- to 10-fold greater for inpatients than for
outpatients. Therefore, 10% was used for the lower bound in the
sensitivity analysis on cost of outpatient FN management.
Clinical Parameters
The clinical parameters and ranges used in sensitivity analyses
are summarized in Table 2. The risk of FN with secondary peg-
ﬁlgrastim prophylaxis of 24.6%, which is also equivalent to that
for no G-CSF, was based on a study by Martin et al. where
patients receiving the TAC regimen initially were precluded from
receiving G-CSF and experienced a high FN rate, and midway,
they were changed to a protocol that required primary G-CSF
support [31,38]. The FN relative risk reduction (RRR) of
73.58% for primary versus secondary prophylaxis (FN risk
6.5% vs. 24.6%) was based on the same study [31]. The range
for FN RRR was varied from 46% [39] to 94% [6]. The FN risk
was assumed to be modestly higher for patients aged 65 years
and older (relative risk [RR] = 1.18) [40–42]. We estimated the
risk of death in patients hospitalized with FN at 3.4% based on
the results reported for breast cancer patients hospitalized with
FN in two population-based studies [32,33]. The case fatality
was assumed to be lower (0.5%) in patients eligible for
Table 1 Model inputs: health-care costs
Parameter Point estimate Range
Cost of pegﬁlgrastim per injection/cycle $2142.24* [28] (30%) $1499.57, $2784.91
Cost of administration of pegﬁlgrastim/injection $20† [29,30] 0, $100§
Hospital cost for an FN hospitalization (facility only) $9745‡ [32] $4000 [32,33], $20,000 [33]
Physician fees for an FN hospitalization (% of hospital cost) 10% [35] 0%, 15%§
Additional costs for subsequent FN-related care (as % of initial FN hospitalization cost) 40% [36] 0%, 40%
Cost of FN outpatient management (as % of initial FN hospitalization cost) 50% [36] 10% [37], 70%§
*2006 average sales price (ASP).
†CMS physician fee schedule, CPT 99211, CPT 90772.
‡Adjusted from 1999 value (i.e., $7100) to 2006 value using consumer price index (CPI) [27].
§Assumption.
CMS, Centers for Medicare and Medicaid Services; CPT, current procedure terminology; FN, febrile neutropenia.
Cost-Effectiveness: Pegﬁlgrastim Prophylaxis 219
outpatient management of FN based on studies that reported
mortality rates of 0% to 2% in various cancer types [43–46].
Breast cancer mortality by stage and year since diagnosis were
obtained from the Surveillance Epidemiology and End Results
(SEER) database [47]. All-cause mortality data were obtained
from National Vital Statistics Reports [48] and were adjusted to
account for deaths because of breast cancer [49].
Health Utilities
Health utility scores, which are numerical judgments (0 = death,
1 = ideal health) of the desirability of a particular health outcome,
were used to calculate quality-adjusted life-years (QALY). Utility
scores for the following health states were obtained from the
literature: breast cancer during chemotherapy, FN, breast cancer
survivor during years 1 to 5 following treatment, and breast
cancer survivor more than 5 years after treatment (Table 2).
Analyses
Costs, FN events, average life expectancy, and average quality-
adjusted life expectancy were estimated for primary prophylaxis
versus secondary prophylaxis. Incremental cost-effectiveness
ratios (ICERs) were calculated: cost/FN event avoided, cost/life-
year gained (LYG), and cost/QALY gained. Because no costs of
interest to this study were modeled beyond 1 year, only future
effectiveness measures such as LYG and QALY saved were dis-
counted, using a discount rate of 3% per annum in the base case
[50].
Two scenarios were analyzed in the model. Scenario 1 con-
sidered only the effect of G-CSF on the incidence and cost of FN
(i.e., assuming G-CSF has no impact on short- or long-term
mortality). Scenario 2 estimated cost/LYG ($/LYG) and cost/
QALY gained ($/QALY gained) under the assumption that
G-CSF also inﬂuences FN-related mortality.
One-way sensitivity analyses were conducted (scenario 2) on
key variables, including FN risks (baseline and RR), FN case-
fatality, RDI-related parameters, cost of drugs, and utility scores.
We performed a sensitivity analysis related to the effect of
prophylaxis on the likelihood of receiving an adequate dose of
chemotherapy (RDI) and the impact of RDI < 85% on survival.
This analysis was performed as an extension to the model, with
branches after chemotherapy indicating the probabilities that the
patient received <85% or85% of the RDI and their subsequent
impact on long-term survival. The baseline (secondary prophy-
laxis) RDI <85% was estimated to be 18.5% regardless of RR of
RDI <85% used [51], although it could be up to 55.5% [52–55].
The RR of receiving <85% RDI between primary versus second-
ary prophylaxis was based on a recent meta-analysis of G-CSF
primary prophylaxis trials [39], which reported mean chemo-
therapy RDI of 95.1% and 86.7% for patients in the primary
prophylaxis arms versus the control arms of the trials, respectively.
G-CSF was used after an FN event in the control arms (i.e.,
secondary prophylaxis) in only 3 out of the 17 trials included in
this meta-analysis. Assuming a normal distribution, the estimated
probabilities of receiving <85%ofRDI in the primary prophylaxis
and control arms were calculated at 40.2% and 47.0%, respec-
tively, resulting in an RR of 0.86. In addition, the cancer types
included in these trials were solid tumors and aggressive non-
Hodgkin’s lymphoma, while our model is for patients with breast
cancer. Despite this imperfect information, we included in the
sensitivity analysis the RR of RDI < 85% of 0.86—1 for primary
versus secondary prophylaxis to account for the potential survival
beneﬁt. The impact of reduced chemotherapyRDIwas assumed to
increase the risk of long-term cancer-speciﬁc mortality by 1.32
based on a long-term follow-up study of clinical trials [56] and
recent observational studies [51,57–59]. The risk of receiving
<85% RDI was assumed to be higher for patients 65 years
compared with younger patients (RR = 1.33) regardless of receipt
of G-CSF prophylaxis [40,42,55,60].
Probabilistic sensitivity analyses were performed on the fol-
lowing parameters with respective distributions: age and cancer
stage (distribution data were from SEER [47]), FN case-fatality
(assumed triangular distribution), FN RRR for primary versus
secondary prophylaxis (assumed triangular distribution), base-
line FN risk (assumed triangular distribution), and cost of initial
FN hospitalization (assumed log normal distribution with a
median of $4000 [32,33] and mean of $9745 [32]). For a trian-
gular distribution, the likeliest value was the point estimate, and
the minimum and maximum values were the lower and upper
bound of the range for each variable, respectively (Tables 1 and
2). The results were plotted on a cost-effectiveness acceptability
curve for scenario 2, which shows the probability that primary
prophylaxis is cost-effective as a function of a payer’s willingness
to pay (WTP) for a unit of health beneﬁt.
Results
Two Scenarios (Table 3)
Primary prophylaxis cost $8703 more per patient than secondary
prophylaxis ($13,791 versus $5,088). In scenario 1, the ICER of
pegﬁlgrastim primary versus secondary prophylaxis was approxi-
mately $48,000/FN episode avoided. When the survival effects
associated with avoiding FN-related mortality were included (sce-
nario 2), the resulting average life expectancy for primary versus
secondary prophylaxis was 15.701 years versus 15.622 years,
respectively, yielding an ICER of $110,000/LYG [95% conﬁdence
interval (CI): $84K/LYG–$136K/LYG]. The ICER from the cost-
utility analysis was $116,000/QALY gained (95% CI: $97K/
QALY–$135K/QALY).
Table 2 Model inputs: clinical parameters
Parameter Point estimate Range
FN risk with secondary prophylaxis/no G-CSF 24.6% [31,38] 20%, 40%
FN RRR: primary vs. secondary prophylaxis 73.58% [31] 46%, 94% [6,39]
FN risk with primary prophylaxis 6.5% [31,77] Vary depending on the two variables above
FN case fatality (% death among hospitalized FN patients) 3.4% [32] 0%, 7% [8,32,33,78]
FN case fatality (% death among FN patients managed at outpatient settings) 0.5% [43–45]
Utility scores for breast cancer during chemotherapy 0.70 [79]
Utility scores for FN hospitalization 0.33* 0.24, 0.42 [66,80]
Utility scores for breast cancer in years 1–5 0.86 [81] 0.30, 0.90
Utility scores for breast cancer in years after year 5 0.96 [82] 0.50, 1.00
*Median of reported range.
BR, baseline risk; FN, febrile neutropenia; G-CSF, granulocyte colony-stimulating factor; OR, odds ratio; RDI, relative dose intensity; RR, relative risk; RRR, relative risk reduction.
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One-Way Sensitivity Analyses
In one-way sensitivity analyses using scenario 2 as the reference
case, the results were sensitive (in order) to the following vari-
ables: FN case-fatality, FN RRR, age at breast cancer diagnosis,
baseline FN risk without primary G-CSF prophylaxis, peg-
ﬁlgrastim cost, cancer stage, utility scores after year 5, cost of
initial FN hospitalization, number of chemotherapy cycles, RR of
chemotherapy RDI < 85% for primary versus secondary prophy-
laxis, proportion of FN treated at outpatient settings, discount
rate, and utility score for the ﬁrst year post-chemotherapy and
years 2–5. Results were less sensitive (or not sensitive at all) to
other variables, including subsequent FN-related care cost, cost
of administering pegﬁlgrastim, proportion of FN events that
occurred in the ﬁrst cycle, outpatient cost, physician fee, and
utility scores for chemotherapy treatment and FN hospitalization
(Fig. 2). When FN case fatality was <2%, the ICER exceeded
$200,000/QALY gained. When varying all other variables within
the speciﬁed ranges, the ICER did not exceed $200,000/QALY
gained except for when the age at diagnosis was near 80 years.
The ICER was $156,000/QALY for baseline risk of FN at 20%,
and $49,000/QALY for baseline risk of FN at 40%. When
adding the potential long-term survival beneﬁt of pegﬁlgrastim
associated with achieving optimal chemotherapy dose intensity
to the beneﬁts of avoiding FN-related mortality (RR of RDI
<85% was 0.86), the ICER was $74,000/QALY gained.
Probabilistic Sensitivity Analyses
In the probabilistic sensitivity analysis for scenario 2, the
probability that pegﬁlgrastim primary prophylaxis would be
considered cost-effective at the threshold value compared with
secondary prophylaxis was 12% for a WTP of $50,000/QALY
gained, 40% for a WTP of $100,000/QALY gained, and 75% for
a WTP of $200,000/QALY gained (Fig. 3).
Discussion
Using simulation modeling, we evaluated the cost-effectiveness of
pegﬁlgrastim as primary versus secondary prophylaxis for women
with breast cancer receiving chemotherapy that carries an FN risk
of approximately 20% or higher. This is the ﬁrst analysis of
primary prophylaxis with G-CSF to consider FN-related survival
beneﬁts and potential long-term survival beneﬁts because ofmain-
taining chemotherapy dose intensity. Prior economic assessments
of G-CSFwere primarily cost-minimization studies [11–13,61,62]
that assumed no difference in clinical outcomes that inﬂuence
patient survival or quality of life. These studies estimated that
G-CSF ranged from being cost-saving [12,13] to costing $48,000
(£37,000) per FN event avoided [11]. A modeling study by
Silber et al. [63] also simulated patients undergoing adjuvant
chemotherapy; however, they considered the cost-effectiveness of
using G-CSF starting in cycle 2 in patients with breast cancer
considered at high risk based on their response to chemotherapy
in the ﬁrst cycle, not primary prophylaxis in cycle 1 as is cur-
rently recommended by clinical guidelines. Because of the hier-
archy of evidence G-CSF use FN-related mortality, and a direct
link between G-CSF use and long-term cancer-related survival,
we considered two scenarios in the core model. Scenario 1 was
supported by the strongest evidence, in which we considered
Table 3 Cost-effectiveness of pegﬁlgrastim as primary versus secondary prophylaxis against febrile neutropenia (FN) for women receivingTAC regimen
Cost ($)
Scenario 1 Scenario 2 (95% credibility interval)
Risk of FN LY QALY
Secondary prophylaxis 5,088 24.6% 15.622 14.487
Primary prophylaxis 13,791 6.5% 15.701 14.563
ICER — $48K/FN event avoided $110K/LYG ($84K/LYG–$136K/LYG) $116K/QALY ($97K/QALY–$135K/QALY)
Scenario 1: pegﬁlgrastim only impacts the frequency of FN but has no inﬂuence on FN mortality, or RDI and its long-term survival beneﬁt. Scenario 2: pegﬁlgrastim impacts the frequency of
FN and the mortality associated with those events, but has no inﬂuence on RDI and its long-term survival beneﬁt.
ICER, incremental cost-effectiveness ratio; K, 1000; LY, life-year; LYG, life-years gained; QALY, quality-adjusted life-years; TAC, docetaxel, doxorubicin/docetaxel, or docetaxel/doxorubicin/
cyclophosphamide.
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Incremental Cost/Eff ($/QALY)
0K 100K 200K 300K
FN case fatality among FN patients who were hospitalized: 0.07 to 0
FN RRR: primary vs. secondary prophylaxis: 0.94 to 0.46
Age at diagnosis: 30 to 80
Baseline FN risk: 0.4 to 0.2
Cost of pegfilgrastim per injection: 1499.57 to 2784.91
Cancer stage: 1 to 3
Utility score for cancer survivors after year 5: 1 to 0.5
Cost of initial FN hospitalization: 20000 to 4000
Number of chemotherapy cycles: 4 to 6
Relative risk of RDI<85%: primary vs. secondary: 0.86 to 1
Proportion of FN treated at outpatient: 0 to 0.25
Discount rate: 0.03 to 0.05
Utility score for first year and subsequent years 2-5: 0.9 to 0.3
Subsequent FN-related care cost: 0 to 0.40
Cost of administering pegfilgrastim per cycle: 0 to 100
Proportion of FN events occurred in first cycle: 0.75 to 0.50
Utility score for breast cancer with chemo treatment: 0.50 to 0.90
Outpatient cost (% of cost for FN hospitalization): 0.10 to 0.70
Physician fee (% of cost for FN hospitalization): 0 to 0.15
Utility score for FN hospitalization: 0.24 to 0.42
Figure 2 Tornado diagram showing results of one-
way sensitivity analysis for scenario 2: primary
versus secondary prophylaxis with pegﬁlgrastim.Top
bar was right truncated. FN, febrile neutropenia;
QALY, quality-adjusted life-year; RDI, relative dose
intensity; RRR, relative risk reduction.
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only the effect of G-CSF on the incidence and cost of FN and
assumed that G-CSF has no impact on near- or long-term mor-
tality, and scenario 2 was supported by moderate evidence, in
which we assumed that primary prophylaxis reduced short-term
FN mortality. In the sensitivity analysis, we considered the
enhanced long-term survival by increasing the likelihood that
patients will receive the full planned chemotherapy dose.
The cost-effectiveness of pegﬁlgrastim prophylaxis at
$116,000/QALY in scenario 2 (assuming G-CSF impacts the
frequency of FN and the mortality associated with those events,
but has no inﬂuence on RDI and its long-term survival beneﬁt) is
less favorable than many health-care interventions, but compares
favorably with other supportive care therapies in cancer, includ-
ing pamidronate for preventing skeletal events in patients
with bone metastases ($108,200–$305,300/QALY) [64] and
ondansetron for cisplatin-induced emesis ($190,000/QALY to
$460,000/QALY) [65]. The cost-effectiveness of pegﬁlgrastim
primary prophylaxis is less favorable than the addition of
taxanes to adjuvant chemotherapy regimens ($27,000/QALY)
[66,67], but similar to trastuzumab for treatment of metastatic
breast cancer ($125,100/QALY) [68], both considered standards
of care. Using the most conservative scenario (i.e., scenario 1),
pegﬁlgrastim as primary prophylaxis would be considered cost-
effective for decision-makers if they were willing to pay $48,000
or more to avoid an FN event.
The primary limitations of our analysis are the lack of direct
evidence linking G-CSF use with a reduction of FN-related mor-
tality and improvements in long-term cancer-speciﬁc survival.
Although individual trials were not designed to assess the impact
of G-CSF on neutropenia-related mortality, a recent meta-
analysis of 12 randomized controlled clinical trials found that
patients receiving G-CSF were less likely to die of infectious
complications (1.5%) compared with control subjects (2.8%;
P = 0.018). Similarly, G-CSF has not been shown to improve
cancer outcomes by allowing chemotherapy to be delivered at
planned dose intensity. The aforementioned meta-analysis found
that among trials reporting chemotherapy dose intensity (1942
patients), the average dose intensity was 86.7% for controls
versus 95.1% for patients receiving G-CSF (P = 0.001) [39].
Although observational studies suggest that patients with breast
cancer who receive chemotherapy doses consistent with those
demonstrated to be effective in clinical trials have lower relapse
rates and improved overall survival [51,56–59], further research
is needed to establish the RDI of chemotherapy needed to assure
optimal outcomes. For patients at a moderate risk of FN, includ-
ing these additional health beneﬁts in the model had a modest
impact on the cost-effectiveness of G-CSF (i.e., the ICER could be
reduced to $74,000/QALY gained).
This analysis was limited to pegﬁlgrastim and did not consider
other G-CSFs recommended in the guidelines, namely ﬁlgrastim
(Neupogen, Amgen Inc. Thousand Oaks, CA) and sargramostim
(Leukine; Bayer HealthCare Pharmaceuticals, Wayne, NJ).
Although sargramostim has been available since 1991 [69], its use
in this setting has been limited by a paucity of data demonstrating
efﬁcacy in reducing FN in patients receiving myelosuppressive
chemotherapy and the absence of an approved indication [70–72].
Filgrastim should have similar to or worse cost-effectiveness than
pegﬁlgrastim primary prophylaxis because of its comparable or
more expensive cost [4,5,73] and comparable or worse efﬁcacy in
reducing FN rates [74]. A recent study showed that prophylactic
administration of pegﬁlgrastim was cost saving compared to both
ﬁlgrastim and noG-CSF [75].When biosimilar ﬁlgrastim becomes
available, it would be reasonable to compare its costs and effects
with those of pegﬁlgrastim.
Our analysis considers the health payer’s perspective, whereas
a societal perspective may be important in other circumstances
[76]. Including indirect costs such as patient time, caregiver costs,
and lost productivity may improve the cost-effectiveness of
primary prophylaxis because of primary prophylaxis’ beneﬁcial
impact on FN-related morbidity and short-term and long-term
mortality.
Lastly, our model excluded the cost of chemotherapy. The
costs of chemotherapy depend on the number of chemotherapy
cycles received. If a patient dies from an FN event during che-
motherapy, presumably no further costs would be incurred after
the patient died. Excluding the cost of chemotherapy thus biased
the results against G-CSF secondary prophylaxis (as chemo-
therapy costs are saved when patients die from FN events).
Nevertheless, because the overall mortality because of FN was
very low, eliminating this bias is unlikely to have a meaningful
impact on the results and conclusions.
Myeloid growth factor guidelines published by the ASCO,
NCCN, and EORTC support the use of primary prophylaxis in
patients receiving chemotherapy regimens associated with a risk
of FN of 20% or higher [1,7,8]. The risk of FN associated with
particular chemotherapy regimens is based on data reported
by randomized controlled trials, which typically include highly
selected patient populations. For this reason, these guidelines
also advise consideration of additional risk factors in estimating
a patient’s individual FN risk. Our model does not account for
factors other than chemotherapy and age that might inﬂuence
a patient’s risk for FN. Retrospective studies ﬁnd that much of
the G-CSF treatment in the community is given as secondary
prophylaxis [9]. Programs for changing practice to providing
G-CSFs as primary prophylaxis in appropriate patients would
likely improve FN-related patient outcomes. Our study suggests
that for women with breast cancer undergoing chemotherapy
with moderate myelosuppressive risk, such programs may also be
cost-effective if program costs are modest and result in signiﬁcant
changes in prescribing patterns. Further assessments of the direct
impact of G-CSFs on both short-term and long-term survival are
needed to substantiate our ﬁndings.
Source of ﬁnancial support: This study was supported by Amgen Inc.,
Thousand Oaks, CA, USA.
Supporting information for this article can be found at [1S]: http://
www.ispor.org/publications/value/ViHsupplementary.asp.
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